A Phase I Dose-Escalation Study of emd 1214063, an Oral Selective CMET Inhibitor, in Patients with Advanced Solid Tumors

Autor: M. Boyer, Masahiro Tsuboi, M. Laniado, T. Nukiwa, Kazuhiko Nakagawa, Hirohisa Yoshizawa, S. Kobayashi, Filip Janku, M. Takeda, Manfred B. Klevesath, Jun Sakakibara-Konishi, W. Uhl, K. Arakawa, Akihiko Gemma, N. Omachi, T. Tsuji, A. Tamiya, T. Yoshino, Yoshiki Ishii, N. Yamamoto, G. Falchook, T. Kawaguchi, Satoshi Oizumi, Luis Paz-Ares, Gerald S. Falchook, Andreas Johne, Y-L. Wu, J-C. Soria, Isamu Okamoto, P. Rougier, S. Atagi, A. Campbell, H. Lannert, Razelle Kurzrock, T. Shiroyama, Siquing Fu, K. Asami, H. Isobe, A. Ohtsu, V. Antic, S.-Y. Lee, K. Park, H. Crane, C.-M. Tsai, Sojiro Morita, Ralph Zinner, Jennifer J. Wheler, M. Wirth, Stephen P. Letrent, Sarina Anne Piha-Paul, Pasi A. Jänne, N. Yoshizuka, M. Tamiya, Tony Mok, K. Takeda, Motoki Yoshida, M. D. Rutstein, J.J. Wheler, H. Suzuki, Thierry Gil, H. Tada, S. Ballal, A. Grothey, S. Zastrow, N. Okamoto, Akira Inoue, Y. Ichinose, K. Sugio, S. Minomo, Aung Naing, Ian Taylor, S. Nakamura, Yoichi Nakanishi, Joe O'Connell, Y. Saijyo, J. T.abernero, Jane Q. Liang, F. Nasroulah, Suresh S. Ramalingam, K. O'Byrne, T. Mitsudomi, Axel Heidenreich, N. Morishita, V. Jego, K. Okishio, K. Yamazaki, Jürgen E. Gschwend, T. Hirashima, David S. Hong, M. Zühlsdorf, T. Yamanaka, D.S. Hong, X. Zhang, Apostolia-Maria Tsimberidou, J. Gerloff, A. Miao, Koichi Hagiwara, Kazuhiko Kobayashi, Hesham M. Amin

Publikováno v: Annals of Oncology. 23:xi21

Background The cell surface receptor tyrosine kinase c-Met and its ligand, the hepatocyte growth factor (HGF), are implicated in tumor cell migration, invasion, survival and proliferation. EMD 1214063 is a novel potent and highly selective reversible

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c6086b2b09f0632a724a6c60c4de3b1
https://doi.org/10.1093/annonc/mds551